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Abstract Sleep disturbances are among the most frequent
and incapacitating non-motor symptoms of Parkinson’s
disease (PD), and are increasingly recognized as an
important determinant of impaired quality of life. Here we
review several recent developments regarding the recog-
nition and diagnosis of sleep disorders in PD. In addition,
we provide a practical and easily applicable approach to
the diagnostic process as a basis for tailored therapeutic
interventions. This includes a stepwise scheme that guides
the clinical interview and subsequent ancillary investiga-
tions. In this scheme, the various possible sleep disorders
are arranged not in order of prevalence, but in a ‘differ-
ential diagnostic’ order. We also provide recommendations
for the use of sleep registrations such as polysomnography.
Furthermore, we point out when a sleep specialist could be
consulted to provide additional diagnostic and therapeutic
input. This structured approach facilitates early detection
of sleep disturbances in PD, so treatment can be initiated
promptly.
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Introduction
Sleep disorders are among the most common non-motor
symptoms in Parkinson’s disease (PD), with an estimated
prevalence of 65 % to more than 95 % [19, 41, 46, 63].
Sleep disorders negatively affect the quality of life [54, 55,
58]. Fortunately, specific treatment options are available,
but adequate treatment requires a precise and timely
diagnosis of the specific sleep disorder at hand. This rec-
ognition and diagnosis remain challenging in everyday
clinical practice because of the wide variety and intricate
combinations of sleep disorders in PD.
The whole gamut of sleep disorders may occur in PD,
including excessive daytime sleepiness, insomnia, noctur-
nal motor symptoms and sleep-related breathing disorders.
Three main groups of causes can be identified. Sleep
problems can be a primary disease symptom caused by
neuronal degeneration in sleep-regulating brain regions. An
example is EDS in patients with cognitive decline [64].
Second, sleep may be disrupted by other symptoms of PD,
such as nocturnal motor symptoms (e.g., difficulty turning
in bed) or autonomic dysfunction (e.g., nocturia). Third,
many drugs used in the treatment of PD can affect sleep
[18, 29, 46, 48, 53]. For example, selegiline—which is
metabolized to methamphetamine and amphetamine—may
cause insomnia [12].
Most sleep disturbances can be diagnosed and treated by
a movement disorders specialist. However, the diversity
and complex origin of sleep disorders in PD may compli-
cate the diagnostic trajectory. Ancillary investigations are
needed occasionally, including polysomnographic record-
ings. In specific cases, the diagnostic and therapeutic help
of a sleep medicine specialist can be useful.
To adequately treat sleep disorders in PD, an accurate
diagnosis is crucial. Treatment options are diverse and
M. Louter  W. C. C. A. Aarden  S. Overeem
Sleep Medicine Centre ‘Kempenhaeghe’, Heeze,
The Netherlands
M. Louter  W. C. C. A. Aarden  J. Lion 
B. R. Bloem  S. Overeem (&)
Department of Neurology, Donders Institute for Brain, Cognition
and Behaviour, Radboud University Nijmegen Medical Centre,
PO Box 9101, 6500 HB Nijmegen, The Netherlands
e-mail: S.Overeem@neuro.umcn.nl
123
J Neurol (2012) 259:2031–2040
DOI 10.1007/s00415-012-6505-7
depend on the specific sleep disorder(s) that are present. In
Table 1, some of the most common sleep disorders are high-
lighted, together with specifically tailored treatment options.
For more elaborate details on the treatment of sleep disorders
in PD, we refer to previously published reviews [4, 44].
The purpose of this article is twofold. We highlight the
most important recent developments that have clinical
relevance for the (differential) diagnosis of sleep disorders
in PD. In addition—and based on this new knowledge—we
provide a practical, easily applicable approach to the rec-
ognition and diagnosis of sleep disorders in PD and atyp-
ical parkinsonian syndromes.
Sleep diagnostics
The sleep history
The clinical interview remains the single most important
diagnostic instrument. Although sleep disorders are com-
mon in PD, they are not always mentioned spontaneously
by the patient, as was recently shown [11]. A few quick
screening questions, probing both nocturnal sleep and
daytime sleepiness (see Table 2), should be asked on a
regular basis in every PD patient. When these questions
raise suspicion of a relevant sleep disorder, a structured
history is the essential starting point of the diagnostic tra-
jectory. Table 2 describes the various topics that should be
covered in such a comprehensive sleep history.
Sleep questionnaires
Sleep questionnaires can help to collect data in a standard
fashion, although they are no substitute for a personal
Table 1 Therapeutic options of the most common sleep disorders in PD
Excessive
daytime
sleepiness
Disrupted nocturnal
sleep
Improve nocturnal sleep
Medication side effect If possible discontinue or
change medication
Primary hypersomnia Stimulant medication
• Modafinil [1]
• Methylphenidate
(no controlled studies)
Nocturnal
motor
symptoms
Nocturnal ‘‘off’’ • Slow release levodopa
preparation [37]
• Continuous
dopaminergic
stimulation (apomorfine,
rotigotine, duodopa) [56,
67]
Restless legs syndrome,
periodic limb
movement disorder
• Increase nighttime dose
of dopaminergic
medication [25]
• Opiate [25]
• Gabapentin [25]
REM sleep behavior
disorder
• Clonazepam [59]
• Melatonin [6]
Sleep-related
breathing
disorder
Obstructive sleep apnea • Continuous positive
airway pressure [44]
Nocturnal stridor • Continuous positive
airway pressure [26, 35,
36]
• Tracheotomy [61]
Table 2 Key elements of the sleep history for PD patients
Screening questions
Sleep onset insomnia (sleep latency [30 min)
Frequent awakenings
Non-restorative sleep (unrefreshed in the morning, tiredness/
sleepiness just after awakening)
Daytime sleepiness (either unwanted sleep episodes or napping)
When a sleep disorder is suspected
Check habitual bedtimes, sleep latency, number and duration
of awakenings, total sleep time
Screening for nocturnal motor symptoms including
‘off’ symptoms and RBD
Screening for nocturia, nocturnal pain
Screening for sleep-related breathing disorders
Screening for mood and anxiety disorders, hallucinations
Daytime sleepiness: frequency, warning signs, driving
Detailed medication schedule, relation to sleep symptoms
Further questioning
Sleep relating breathing disorders
Snoring, witnessed apneas, nocturnal stridor, daytime stridor
Nocturia, night sweats, dry mouth in the morning, morning
headaches
REM sleep behavior disorder
Sleep talking, shouting, swearing
Gross body movements resembling ‘dream enactment’
(often aggressive)
Restless legs syndrome
Check diagnostic criteria (see Table 3)
Nocturia
Frequency, volume, urologic symptoms during the day
Fluid intake in the evening, caffeine and alcohol use,
medication such as diuretics
Primary insomnia
Circumstances around onset, sleep hygiene, extending
bed times ‘to try and catch some sleep’
Worrying when lying awake, frequently checking the clock
Mood and other co-morbid disorders
Excessive daytime sleepiness
Frequency and duration of unintentional sleep episodes
Circumstances, warning signs, relation with dopaminergic
medication
Driving, effect of planned naps
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clinical interview. In the past years, several sleep ques-
tionnaires have been developed to indentify sleep disorders
in PD. A recent study of The Sleep Scale Task Force
reviewed these scales and made recommendations for their
use [31]. The Pittsburgh Sleep Quality Index (PSQI) is a
well-validated measure of nocturnal sleep quality and
severity of nighttime sleep disturbances [8]. The Parkin-
son’s Disease Sleep Scale (PDSS) is a more general
scale that specifically rates sleep problems in PD [10]. The
Epworth Sleepiness Scale (ESS) is recommended to screen
for excessive daytime sleepiness and to rate its severity
[38]. A specific screening for sleep attacks is provided by
The Inappropriate Sleep Composite Score (ISCS) [30].
Nighttime sleep problems and excessive daytime sleepiness
are both part of the Scales for Outcomes in Parkinson’s
Disease Sleep (SCOPA-SLEEP), but this scale has not yet been
validated against other—objective—sleep measures [43].
The Sleep Scale Task Force has also commented on the
fact that many available sleep questionnaires offer an
overall rating of the severity of night- or daytime sleep
problems, but are not intended to diagnose a specific sleep
disorder. Recently, the PDSS has been revised and updated
to tackle this issue. The PDSS-2 now screens for sleep
disorders that are common in PD, such as restless legs
syndrome, nocturnal akinesia, and/or pain and sleep apnea
[66]. The PDSS-2 was validated using a semi-structured
interview, but a validation against objective measurements
such as polysomnography has not yet been performed.
Sleep registrations
A number of neurophysiological studies allow for the
assessment of sleep architecture and the detection of noc-
turnal sleep disorders as well as excessive daytime sleep-
iness, but these sleep registrations should always be
interpreted carefully and in combination with the clinical
interview. The mainstay technique is polysomnography
(PSG): the simultaneous recording of multiple signals to
measure both sleep itself and associated physiological
parameters such as breathing. Additional audiovisual
recording can be very useful, especially for diagnosing
nocturnal movement disorders, such as REM sleep
behavior disorder. Excessive daytime sleepiness can be
objectified using the Multiple Sleep Latency Test (MSLT).
Poryazova et al. [52] found a significant correlation
between ESS scores [10 (indicating excessive daytime
sleepiness) and short mean sleep latency (B5 min) as mea-
sured with the MSLT. Although in daily practice the clinical
interview and additional questionnaires are often sufficient to
diagnose excessive daytime sleepiness, an MSLT can be
considered when an objective diagnosis is needed (e.g., in
relation to driving) or when there is difficulty separating
sleepiness from related complaints of fatigue.
Diagnostic strategy
Most reviews on sleep disorders in PD are organized based
on the (presumed) pathophysiology, but lack a clear
structure that can aid in the differential diagnosis. Adopting
a systematic way of thinking about disturbed sleep facili-
tates the clinical interview and reduces the risk of missing
sleep disorders. In Fig. 1, we have put the various
PD-related sleep disorders into a flowchart, which can be
followed in every patient. The order is based on differential
diagnostic grounds, and is not related to prevalence or
severity. The various disorders are categorized into
‘‘excessive daytime sleepiness’’ and ‘‘disturbed nocturnal
sleep.’’ The latter category is in turn subdivided into
‘‘nocturnal motor symptoms,’’ ‘‘sleep-related breathing
disorders’’ and ‘‘other causes of insomnia.’’
The diagnostic process starts with determining whether
daytime sleepiness is present. If so, one should decide if
disturbed nocturnal sleep is a likely culprit, in which case
the flowchart should be followed in that direction. If not,
side effects of medication and primary hypersomnias
remain possible causes for excessive daytime sleepiness.
Nocturnal motor symptoms are the primary cause to be
checked when nighttime sleep is disturbed. Sleep-related
breathing disorders should then be checked for. What
remains are several other causes of insomnia, with their
associated diagnostic trajectory. Importantly, one should
always consider the fact that more than one sleep disorder
can be present.
Table 3 explains the various categories of the flowchart,
with the associated diagnostic tools. The table further
shows in which cases the help of a sleep medicine spe-
cialist could be considered for additional diagnostic and
therapeutic input.
Excessive daytime sleepiness
Excessive daytime sleepiness versus ‘sleep attacks’
The most important characteristic of excessive daytime
sleepiness (EDS) is the tendency to actually fall asleep
during the day, usually accompanied by a ‘building’ feeling
of sleepiness. Prevalence rates of EDS in PD range from
29 % to almost 60 % [27, 30, 48, 52, 64, 69]. The term
‘sleep attacks’ is often intermingled with EDS, but this is
not justified. Sleep attacks are sudden, irresistible sleep
episodes, often without warning signs. In the late 1990s,
Frucht et al. [23] described sleep attacks in PD patients
while driving after starting treatment with dopamine ago-
nists. A large study from Canada, including 638 consecu-
tive PD patients, showed a prevalence of sleep attacks
while driving of 3.8 % [30]. In only 0.7 % of patients,
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sleep episodes occurred without any warning signs. Sleep
attacks can also occur during activities other than driving.
Paus et al. [51] reported sudden onset sleep while engaged
in some form of activity (e.g., during a meal or phone call)
in 580 of 2,952 patients (19.6 %). Ko¨rner et al. [39] sug-
gested even higher prevalence rates, with sudden sleep
episodes in 42.5 % of 6,620 PD patients, but only in
19.2 % during activities.
Excessive daytime sleepiness versus fatigue
Although patients often describe EDS as ‘fatigue,’ these
represent two distinct symptoms. Fatigue is a feeling of
tiredness and lack of energy, but does not result in
unwanted sleep episodes [21]. Moreover, EDS and fatigue
are differentially associated with clinical features of PD
[69]. Specifically, fatigue is associated with higher scores
on the motor part of the Unified Parkinson’s Disease
Rating Scale (UPDRS III), higher Hoehn and Yahr stage
and higher scores on a depression rating scale. Conversely,
EDS is associated with the disease duration and type of
dopaminergic treatment; patients with non-ergot dopamine
agonists had higher scores on the ESS [69].
Causes of excessive daytime sleepiness
Many studies have described a correlation between EDS
and the use of dopaminergic drugs [18, 29, 48]. A recent
study reported a dose-dependent effect of mean overall
levodopa-equivalent dose and EDS, as measured with both
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ESS and MSLT. Importantly, this study analyzed the use of
dopamine agonists, either alone or in combination with
levodopa, but not levodopa alone [52]. However, some
authors found no relation between EDS and medication, and
concluded that sleepiness was related directly to PD pathology
[3]. Recent studies focused on the possibility that EDS in PD
may be related to damage to the hypothalamic sleep-regulat-
ing hypocretin system. Thus, Fronczek et al. [22] found a
significant decrease in the number of hypocretin neurons and a
lower hypocretin-1 concentration in ventricular CSF in post-
mortem material. In the same issue of Brain, Thannickal et al.
[65] also described a decrease in hypocretin neurons, which
correlated with disease stage. Unfortunately, these patholog-
ical findings do not translate into a clinically useful test: one
study reported low hypocretin-1 levels in spinal CSF in only
two out of eight PD patients with EDS, and other research
groups found normal spinal CSF levels [5, 50, 52, 73].
Nocturnal motor symptoms
Nocturnal motor symptoms are an important cause of sleep
disturbances in PD, and include nocturnal ‘off’ symptoms
and dyskinesias, in addition to primary sleep disorders such
as restless legs syndrome (RLS), periodic limb movement
disorder (PLMD) and REM sleep behavior disorder (RBD).
Nocturnal ‘‘off’’
Lees was the first to describe the phenomenon of nocturnal
‘‘off’’ in 1988, reporting that 65 % of PD patients had
difficulty turning around in bed [41]. Nowadays it is widely
appreciated that nocturnal ‘‘off’’ symptoms contribute to
impaired mobility in bed, making it difficult to turn around
or find a comfortable sleep position. Surprisingly, no one
has studied the influence of impaired bed mobility on sleep
quality and sleep structure. The diagnosis of sleep prob-
lems caused by nocturnal ‘‘off’’ is primarily based on the
clinical interview. There is a major need for objective
measurements to diagnose sleep disturbances caused by
nocturnal ‘‘off’’ periods. Recently, Bossenbroek et al. [7]
validated the use of a tri-axial accelerometer to measure the
intensity of movements in addition to body position during
sleep. This seems to be a promising new way to objectively
measure nocturnal ‘‘off’’ periods in PD, even in the home
situation.
Table 3 Diagnostic outline for sleep disorders in PD
Main sleep symptom Etiological category Diagnostic strategy
Daytime Excessive daytime
sleepiness
Disturbed nocturnal sleep
(see nighttime)
Medication side effect Clinical history, dedicated questionnaires (e.g., ESS), lower dose or
change to different drug
Primary hypersomnia Clinical history (exclusion of other causes), dedicated
questionnaires (e.g., ESS), MSLT
Nighttime Nocturnal motor
symptoms
Nocturnal ‘off’: tremor, rigidity,
akinesia, dystonia
Clinical history, when in doubt: video-polysomnography
Dyskinesias Clinical history
Restless legs syndrome Clinical criteria, laboratory investigations (e.g., ferritin levels)
Periodic limb movement disorder Polysomnography (interpretation by sleep specialist)
REM sleep behavior disorder Clinical history, video-polysomnography
Sleep-related
breathing disorders
Sleep apnea syndromes
(obstructive and/or central)
Clinical history, clinical examination, pulmonological
evaluation, polygraphy/polysomnograpy
Nocturnal stridor Clinical history, polysomnography with synchronous audio
recording, consider laryngoscopy
Other causes of
insomnia
Depression, anxiety Clinical history, diagnostic questionnaires, assessment by
psychiatrist
Nightmares, hallucinations,
psychosis
Clinical history, assessment by psychiatrist
Cognitive decline and dementia Neuropsychological tests, check underlying treatable causes
Nocturia Clinical history, physical examination, urological evaluation
Nocturnal pain Clinical history, screen for comorbidity, physical examination
Medication side effects Clinical history, lowering dose or change to different drug
Primary insomnia Clinical history, exclusion of other causes
In bold typical indications for consultation with a sleep medicine specialist
ESS Epworth Sleepiness Scale, MSLT multiple sleep latency test
J Neurol (2012) 259:2031–2040 2035
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Dyskinesias
Levodopa-induced dyskinesias are sometimes more intense
in the evening, for example because of a cumulative effect
of repeated doses of long-acting dopaminergic agents.
Biphasic dyskinesias can also be severe in the evening after
patients have taken their final evening dose of medication.
Patients may report that these dyskinesias hamper the onset
of sleep or disturb sleep when dyskinesias return during
nighttime arousals [47]. However, no formal data are
available on the prevalence and influence of nocturnal
dyskinesias on sleep in PD patients.
Restless legs syndrome
The dopaminergic system plays an important role in the
pathophysiology of RLS, so it is to be expected that the
prevalence of RLS is increased in PD. However, this
relation between RLS and PD is not completely clear.
Epidemiological studies yielded conflicting results. Some
authors reported increased RLS prevalence rates of up to
21 % in Caucasian PD patients [49]. In contrast, a recent
study could not confirm this high prevalence, although the
study population was on relatively high levodopa doses,
which may have influenced the outcomes [70].
RLS and PD may share a therapeutic response to
dopaminergic drugs, but other characteristics point to a
differential or additional effect of PD pathology. Compared
to idiopathic RLS patients, PD patients with RLS have a
higher age of onset and less often a positive family history
of RLS [49]. In addition, studies using transcranial
sonography found a significantly decreased echogenicity of
the substantia nigra in patients with idiopathic RLS com-
pared to PD patients with or without RLS, and healthy
controls [40, 57].
Regardless of the exact prevalence, it remains important
to be vigilant for the presence of restless legs in PD,
because RLS has a negative influence on quality of life,
while the symptoms can often be treated satisfactorily.
Note that specific PD symptoms—such as akathisia—may
obscure the diagnosis of RLS. Therefore, it is important to
adhere to the diagnostic guidelines, which emphasize the
presence of all four core features (Table 4) [2]. Secondary
RLS should be excluded using appropriate investigations.
In the general population, iron deficiency is the most
common cause of secondary RLS, and one study confirmed
this association in PD patients with RLS [10]. Ferritin
levels are the best marker for iron deficiency [2, 10].
Periodic limb movement disorder
Periodic limb movement disorder (PLMD) often co-occurs
with RLS, but is a distinct disorder. Literature on the
presence of PLMD in PD is scarce. Arnulf et al. [3] found
PLMD in 15 % of a PD patient cohort, which is clearly
higher than population estimates (which range around 8 %)
[60]. Another study found more periodic limb movements
in patients with PD compared to controls, but also com-
pared to patients with MSA [71]. It is often assumed that
periodic limb movements result in arousals from sleep,
resulting in daytime symptoms. However, Arnulf et al. [3]
found no association between the presence of PLMD and
daytime sleepiness. Indeed, periodic limb movements are
often asymptomatic, making it difficult to assess their
clinical significance [9].
REM sleep behavior disorder
RBD is a parasomnia resulting from loss of normal atonia
during REM sleep, leading to vigorous behavior with
enactment of vivid and frightening dreams. The excessive
motor activity may even result in injuries to the patient or
bed partner [15]. During the last decade RBD has been
shown to be a premarker of alpha synucleopathies such as
PD [13, 33]. The prevalence of RBD in PD is estimated
between 15 and 30 % [15, 24, 28].
Given the potential dangers and available treatment
options, asking every PD patient and the bed partner for the
presence of ‘dream enactment’ is recommended (see
Table 1). Eisensehr et al. [17] found frequent misdiagnoses
when RBD is established solely upon the clinical interview.
As RBD also needs to be differentiated from other sleep
disorders, such as obstructive sleep apnea, confusional
arousals, nocturnal hallucinations and nocturnal frontal
seizures, the threshold for doing a PSG should be low, even
when the clinical interview is very typical [34].
The gold standard for diagnosis remains a PSG with
simultaneous audiovisual recording. Video-PSG allows a
confident diagnosis by showing an increase of tonic and
phasic muscle activity in REM sleep, sometimes associated
Table 4 Diagnostic criteria for RLS43
Required criteria
• Uncomfortable and unpleasant sensations in the extremities
(prickling, stinging, itching, ‘like crawling ants,’ sometimes
described as pain), with an urge to move
• The sensations begin or worsen during inactivity
• The sensations and/or urge to move are partially or totally
relieved by movement
• The sensations and/or urge to move display a circadian pattern:
worse in the evening or night compared than the early
morning; or only occurring in the evening or night
Supportive features of RLS
• Positive family history
• Clear beneficial response to dopaminergics
• Presence of periodic limb movements during sleep
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with actual motor behavior. The ‘‘SinBar group’’—a col-
laboration between the sleep groups in Innsbruck and
Barcelona—introduced an EMG montage protocol, and
showed that simultaneous recording of the m. mentalis, m.
flexor digitorum superficialis in the upper limbs and m.
extensor digitorum brevis in the lower limbs provides the
highest rate of phasic EMG activity during REM sleep in
patients with RBD [20]. More recent work evaluated the
diagnostic performance of this EMG montage, showing a
sensitivity of 94.4 %, specificity of 47.2 % and negative
predictive value of 41.9 % [32]. Until recently, however,
no formal cutoff values were available to determine when
phasic or tonic EMG activity in REM sleep is ‘too high.’ In
2010, Montplaisir et al. [45] established the first set of such
parameters for idiopathic RBD, which can be used in a
clinical or research setup. In addition to EMG-based
polysomnographic methods, a polysomnographic video-
based scale is now available to rate the severity of RBD
[62].
In addition to its clinical relevance, RBD also sheds
highly interesting new light onto the regulation of motor
activity in PD. De Cock et al. [16] found a restoration of
normal motor control during nighttime movements in
association with RBD. The majority of bed partners of PD
patients with RBD (87 %) observed an improvement in
movement quality during RBD episodes (faster, stronger or
smoother). Video-PSG studies indeed showed body
movements during REM without obvious signs of Parkin-
sonism during REM. The exact meaning of these obser-
vations remains unclear, but it was hypothesized that these
movements are somehow generated in the motor cortex,
thus bypassing the defective extrapyramidal systems [16].
Sleep-related breathing disorders
Sleep-related breathing disorders are relatively common
among the general population. They are important to
diagnose, as they may not only result in unrefreshing sleep
and daytime sleepiness, but also negatively influence the
long-term cardiovascular risk profile.
The most common forms of sleep-related breathing
disorders are sleep apnea syndromes, divided into two
types: obstructive sleep apnea (OSAS) and central sleep
apnea. OSAS is characterized by repetitive episodes of
complete or partial upper airway obstruction that occur
during sleep. Two recent studies show no increased risk of
OSAS in PD patients [14, 68]. In fact, one study even
found a lower prevalence (27 % in PD, compared to 40 %
in controls referred for daytime sleepiness) [14]. The
frequency of sleep apnea did not differ between unse-
lected PD patients and patients who were referred for
sleepiness. Differences in the patient population as well as
selection of controls may explain the different results
across studies.
Established risk factors for OSAS—such as increased
neck circumference and retrognathia—obviously also
apply to PD patients. However, there is no correlation
between the presence of OSAS and snoring, sleepiness or
elevated body mass index in PD [68].
Although OSAS is not more prevalent in PD patients
compared to controls, the prevalence rate is still 15–30 %
[14, 68], so clinicians should remain vigilant for its pres-
ence. The diagnostic yield of PSG versus limited respira-
tory polygraphy to detect sleep apnea in PD has not been
studied. Given the complexity of sleep disturbances in PD
with a high frequency of combined disorders, we advocate
the use of full PSG whenever a sleep registration is deemed
necessary.
Nocturnal stridor
Nocturnal stridor is a specific sleep-related breathing dis-
order, which is mainly associated with multiple system
atrophy [42]. Its presence has therefore differential diag-
nostic value in the workup of an extrapyramidal disorder.
In addition, stridor is associated with a decreased life-
expectancy [72]. Stridor can be recognized clinically as an
inspiratory vocalization with a strained, harsh and high-
pitched (260–330 Hz) sound during sleep. To formally
diagnose nocturnal stridor, a PSG with audiovisual moni-
toring should be performed.
Other causes of insomnia
When nocturnal motor symptoms and sleep-related
breathing disorders are excluded, several other causes of
disturbed nighttime sleep remain. Together, these may
jointly be referred to as ‘insomnia.’ Up to 60 % of PD
patients complain about insomnia, especially sleep frag-
mentation and early morning awakenings [63]. Insomnia
can take several different forms, manifesting as difficulty
with initiating sleep, maintaining sleep, early-morning
awakenings or a combination of these. However, the
diagnosis ‘insomnia’ should be used with caution.
‘Insomnia’ can have widely varying causes, and the generic
term does not discriminate between them. In Fig. 1, these
causes of problems with sleep initiation or maintenance are
listed.
Conclusions
Sleep disorders are very common in PD, but still their
recognition and diagnosis remain challenging. Our
J Neurol (2012) 259:2031–2040 2037
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proposed diagnostic workup can serve as a basis for tai-
lored therapeutic interventions. The diagnostic armamen-
tarium is extended and refined all the time, for example
yielding well-validated clinical questionnaires or new
devices to measure body movements related to sleep in the
home environment.
Acknowledgments S Overeem, MD, PhD has received research
support from the Netherlands Organization for Scientific Research
(016116371) and received honoraria from UCB Pharma and Boeh-
ringer Ingelheim. B.R. Bloem, MD, PhD, has served as an editorial
board member of Movement Disorders, currently serves as an
editorial board member of Physiotherapy Canada, is Associate Editor for
the Journal of Parkinson’s disease, received honoraria from serving
on the scientific advisory board for Boehringer Ingelheim, Teva,
Glaxo-Smith-Kline and Novartis, and received research support from
the Netherlands Organization for Scientific Research (016076352),
the Michael J. Fox Foundation, the Prinses Beatrix Foundation, the
Stichting Internationaal Parkinson Fonds and the Alkemade Keuls
fonds.
Conflicts of interest None.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J (2003)
Randomized trial of modafinil for treating subjective daytime
sleepiness in patients with Parkinson’s disease. Mov Disord
18:287–293
2. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS,
Montplaisi J (2003) Restless legs syndrome: diagnostic criteria,
special considerations, and epidemiology. A report from the
restless legs syndrome diagnosis and epidemiology workshop at
the National Institutes of Health. Sleep Med 4:101–119
3. Arnulf I, Konofal E, Merino-Andreu M, Houeto JL, Mesnage V,
Welter ML, Lacomblez L, Golmard JL, Derenne JP, Agid Y
(2002) Parkinson’s disease and sleepiness: an integral part of PD.
Neurology 58:1019–1024
4. Barone P, Amboni M, Vitale C, Bonavita V (2004) Treatment of
nocturnal disturbances and excessive daytime sleepiness in
Parkinson’s disease. Neurology 63:S35–S38
5. Baumann C, Ferini-Strambi L, Waldvogel D, Werth E, Bassetti
CL (2005) Parkinsonism with excessive daytime sleepiness—a
narcolepsy-like disorder? J Neurol 252:139–145
6. Boeve BF, Silber MH, Ferman TJ (2003) Melatonin for treatment
of REM sleep behavior disorder in neurologic disorders: results in
14 patients. Sleep Med 4:281–284
7. Bossenbroek L, Kosse N, Ten Hacken N, Gordijn M, Van der
Hoeven J, De Greef M (2010) Validation of the DynaPort
MiniMod during sleep: a pilot study. Percept Mot Skills
111:936–946
8. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ
(1989) The Pittsburgh Sleep Quality Index: a new instrument for
psychiatric practice and research. Psychiatry Res 28:193–213
9. Carrier J, Frenette S, Montplaisir J, Paquet J, Drapeau C,
Morettini J (2005) Effects of periodic leg movements during
sleep in middle-aged subjects without sleep complaints. Mov
Disord 20:1127–1132
10. Chaudhuri KR, Pal S, DiMarco A, Whately-Smith C, Bridgman
K, Mathew R, Pezzela FR, Forbes A, Hogl B, Trenkwalder C
(2002) The Parkinson’s disease sleep scale: a new instrument for
assessing sleep and nocturnal disability in Parkinson’s disease.
J Neurol Neurosurg Psychiatry 73:629–635
11. Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, Mitra T, Frades-
Payo B, Tluk S, Ruessmann A, Odin P, Macphee G, Stocchi F,
Ondo W, Sethi K, Schapira AH, Martinez Castrillo JC, Martinez-
Martin P (2010) The nondeclaration of nonmotor symptoms of
Parkinson’s disease to health care professionals: an international
study using the nonmotor symptoms questionnaire. Mov Disord
25:697–701
12. Chrisp P, Mammen GJ (1991) Selegiline. A review of its phar-
macology, symptomatic benefits and protective potential in
Parkinson’s disease. Drugs Aging 1:228–248
13. Claassen DO, Josephs KA, Ahlskog JE, Silber MH, Tippmann-
Peikert M, Boeve BF (2010) REM sleep behavior disorder pre-
ceding other aspects of synucleinopathies by up to half a century.
Neurology 75:494–499
14. Cochen De Cock V, Abouda M, Leu S, Oudiette D, Roze E,
Vidailhet M, Similowski T, Arnulf I (2010) Is obstructive sleep
apnea a problem in Parkinson’s disease? Sleep Med 11:247–252
15. Comella CL, Nardine TM, Diederich NJ, Stebbins GT (1998)
Sleep-related violence, injury, and REM sleep behavior disorder
in Parkinson’s disease. Neurology 51:526–529
16. De Cock VC, Vidailhet M, Leu S, Texeira A, Apartis E, Elbaz A,
Roze E, Willer JC, Derenne JP, Agid Y, Arnulf I (2007) Resto-
ration of normal motor control in Parkinson’s disease during
REM sleep. Brain 130:450–456
17. Eisensehr I, van Lindeiner H, Jager M, Noachtar S (2001) REM
sleep behavior disorder in sleep-disordered patients with versus
without Parkinson’s disease: is there a need for polysomnogra-
phy? J Neurol Sci 186:7–11
18. Fabbrini G, Barbanti P, Aurilia C, Vanacore N, Pauletti C, Meco
G (2002) Excessive daytime sleepiness in de novo and treated
Parkinson’s disease. Mov Disord 17:1026–1030
19. Factor SA, McAlarney T, Sanchez-Ramos JR, Weiner WJ (1990)
Sleep disorders and sleep effect in Parkinson’s disease. Mov
Disord 5:280–285
20. Frauscher B, Iranzo A, Hogl B, Casanova-Molla J, Salamero M,
Gschliesser V, Tolosa E, Poewe W, Santamaria J (2008) Quantifi-
cation of electromyographic activity during REM sleep in multiple
muscles in REM sleep behavior disorder. Sleep 31:724–731
21. Friedman JH, Brown RG, Comella C, Garber CE, Krupp LB, Lou
J-S, Marsh L, Nail L, Shulman L, Taylor CB (2007) Fatigue in
Parkinson’s disease: a review. Mov Disord 22:297–308
22. Fronczek R, Overeem S, Lee SY, Hegeman IM, van Pelt J, van
Duinen SG, Lammers GJ, Swaab DF (2007) Hypocretin (orexin)
loss in Parkinson’s disease. Brain 130:1577–1585
23. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S (1999)
Falling asleep at the wheel: motor vehicle mishaps in persons
taking pramipexole and ropinirole. Neurology 52:1908–1910
24. Gagnon JF, Bedard MA, Fantini ML, Petit D, Panisset M,
Rompre S, Carrier J, Montplaisir J (2002) REM sleep behavior
disorder and REM sleep without atonia in Parkinson’s disease.
Neurology 59:585–589
25. Garcia-Borreguero D, Larrosa O, Bravo M (2003) Parkinson’s
disease and sleep. Sleep med rev 7:115–129
26. Ghorayeb I, Yekhlef F, Bioulac B, Tison F (2005) Continuous
positive airway pressure for sleep-related breathing disorders in
multiple system atrophy: long-term acceptance. Sleep Med
6:359–362
27. Ghorayeb I, Loundou A, Auquier P, Dauvilliers Y, Bioulac B,
Tison F (2007) A nationwide survey of excessive daytime
2038 J Neurol (2012) 259:2031–2040
123
sleepiness in Parkinson’s disease in France. Mov Disord
22:1567–1572
28. Gjerstad MD, Boeve B, Wentzel-Larsen T, Aarsland D, Larsen JP
(2008) Occurrence and clinical correlates of REM sleep behav-
iour disorder in patients with Parkinson’s disease over time.
J Neurol Neurosurg Psychiatry 79:387–391
29. Happe S, Berger K, Investigators FS (2001) The association of
dopamine agonists with daytime sleepiness, sleep problems and
quality of life in patients with Parkinson’s disease—a prospective
study. J Neurol 248:1062–1067
30. Hobson DE, Lang AE, Martin WRW, Razmy A, Rivest J,
Fleming J (2002) Excessive daytime sleepiness and sudden-onset
sleep in Parkinson disease: a survey by the Canadian movement
disorders group. JAMA 287:455–463
31. Hogl B, Arnulf I, Comella C, Ferreira J, Iranzo A, Tilley B,
Trenkwalder C, Poewe W, Rascol O, Sampaio C, Stebbins GT,
Schrag A, Goetz CG (2010) Scales to assess sleep impairment in
Parkinson’s disease: critique and recommendations. Mov Disord
25:2704–2716
32. Iranzo A, Frauscher B, Santos H, Gschliesser V, Ratti L,
Falkenstetter T, Sturner C, Salamero M, Tolosa E, Poewe W,
Santamaria J, Hogl B (2011) Usefulness of the SINBAR elec-
tromyographic montage to detect the motor and vocal manifes-
tations occurring in REM sleep behavior disorder. Sleep Med
12:284–288
33. Iranzo A, Molinuevo JL, Santamaria J, Serradell M, Marti MJ,
Valldeoriola F, Tolosa E (2006) Rapid-eye-movement sleep
behaviour disorder as an early marker for a neurodegenerative
disorder: a descriptive study. Lancet Neurol 5:572–577
34. Iranzo A, Santamaria J (2005) Severe obstructive sleep apnea/
hypopnea mimicking REM sleep behavior disorder. Sleep
28:203–206
35. Iranzo A, Santamaria J, Tolosa E (2000) Continuous positive air
pressure eliminates nocturnal stridor in multiple system atrophy.
Barcelona Multiple System Atrophy Study Group. Lancet
356:1329–1330
36. Iranzo A, Santamaria J, Tolosa E, et al (2004) Long-term effect of
CPAP in the treatment of nocturnal stridor in multiple system
atrophy. Neurology 63:930–932
37. Jansen EN, Meerwaldt JD (1988) Madopar HBS in Parkinson
patients with nocturnal akinesia. Clin neurol neurosurgery
90:35–39
38. Johns MW (1991) A new method for measuring daytime sleep-
iness: the Epworth sleepiness scale. Sleep 14:540–545
39. Korner Y, Meindorfner C, Moller JC, Stiasny-Kolster K, Haja D,
Cassel W, Oertel WH, Kruger HP (2004) Predictors of
sudden onset of sleep in Parkinson’s disease. Mov Disord
19:1298–1305
40. Kwon DY, Seo WK, Yoon HK, Park MH, Koh SB, Park KW
(2010) Transcranial brain sonography in Parkinson’s disease with
restless legs syndrome. Mov Disord 25:1373–1378
41. Lees AJ, Blackburn NA, Campbell VL (1988) The nighttime
problems of Parkinson’s disease. Clin Neuropharmacol
11:512–519
42. Magalhaes M, Wenning GK, Daniel SE, Quinn NP (1995)
Autonomic dysfunction in pathologically confirmed multiple
system atrophy and idiopathic Parkinson’s disease—a retrospec-
tive comparison. Acta Neurol Scand 91:98–102
43. Marinus J, Visser M, van Hilten JJ, Lammers GJ, Stiggelbout AM
(2003) Assessment of sleep and sleepiness in Parkinson disease.
Sleep 26:1049–1054
44. Menza M, Dobkin RD, Marin H, Bienfait K (2010) Sleep dis-
turbances in Parkinson’s disease. Mov Disord 25(Suppl 1):S117–
S122
45. Montplaisir J, Gagnon JF, Fantini ML, Postuma RB, Dauvilliers
Y, Desautels A, Rompre S, Paquet J (2010) Polysomnographic
diagnosis of idiopathic REM sleep behavior disorder. Mov Disord
25:2044–2051
46. Nausieda PA, Weiner WJ, Kaplan LR, Weber S, Klawans HL
(1982) Sleep disruption in the course of chronic levodopa ther-
apy: an early feature of the levodopa psychosis. Clin Neuro-
pharmacol 5:183–194
47. Obeso JA, Grandas F, Vaamonde J, Luquin MR, Artieda J, Lera
G, Rodriguez ME, Martinez-Lage JM (1989) Motor complica-
tions associated with chronic levodopa therapy in Parkinson’s
disease. Neurology 39:11–19
48. Ondo WG, Dat Vuong K, Khan H, Atassi F, Kwak C, Jankovic J
(2001) Daytime sleepiness and other sleep disorders in Parkin-
son’s disease. Neurology 57:1392–1396
49. Ondo WG, Vuong KD, Jankovic J (2002) Exploring the rela-
tionship between Parkinson disease and restless legs syndrome.
Arch Neurol 59:421–424
50. Overeem S, van Hilten JJ, Ripley B, Mignot E, Nishino S,
Lammers GJ (2002) Normal hypocretin-1 levels in Parkinson’s
disease patients with excessive daytime sleepiness. Neurology
58:498–499
51. Paus S, Brecht HM, Koster J, Seeger G, Klockgether T, Wullner
U (2003) Sleep attacks, daytime sleepiness, and dopamine
agonists in Parkinson’s disease. Mov Disord 18:659–667
52. Poryazova R, Benninger D, Waldvogel D, Bassetti CL (2010)
Excessive daytime sleepiness in Parkinson’s disease: character-
istics and determinants. Eur Neurol 63:129–135
53. Puca FM, Bricolo A, Turella G (1973) Effect of L-dopa or
amantadine therapy on sleep spindles in Parkinsonism. Electro-
encephalogr Clin Neurophysiol 35:327–330
54. Qin Z, Zhang L, Sun F, Fang X, Meng C, Tanner C, Chan P
(2009) Health related quality of life in early Parkinson’s disease:
impact of motor and non-motor symptoms, results from Chinese
levodopa exposed cohort. Parkinsonism Relat Disord 15:767–771
55. Rahman S, Griffin HJ, Quinn NP, Jahanshahi M (2008) Quality of
life in Parkinson’s disease: the relative importance of the symp-
toms. Mov Disord 23:1428–1434
56. Reuter I, Ellis CM, Ray Chaudhuri K (1999) Nocturnal subcu-
taneous apomorphine infusion in Parkinson’s disease and restless
legs syndrome. Acta neurologica Scandinavica 100:163–167
57. Ryu JH, Lee MS, Baik JS (2011) Sonographic abnormalities in
idiopathic restless legs syndrome (RLS) and RLS in Parkinson’s
disease. Parkinsonism Relat Disord 17:201–203
58. Scaravilli T, Gasparoli E, Rinaldi F, Polesello G, Bracco F (2003)
Health-related quality of life and sleep disorders in Parkinson’s
disease. Neurol Sci 24:209–210
59. Schenck C, Mahowald M (1990) Polysomnographic, neurologic,
psychiatric, and clinical outcome report of 70 consecutive cases
with REM sleep behavior disorder (RBD): sustained clonazepam
efficacy in 89.5% of 57 treated patients. Clev Clin J Med
57:10–24
60. Scofield H, Roth T, Drake C (2008) Periodic limb movements
during sleep: population prevalence, clinical correlates, and racial
differences. Sleep 31:1221–1227
61. Silber MH, Levine S (2000) Stridor and death in multiple system
atrophy. Mov Disord 15:699–704
62. Sixel-Doring F, Schweitzer M, Mollenhauer B, Trenkwalder C
(2011) Intraindividual variability of REM sleep behavior disorder
in Parkinson’s disease: a comparative assessment using a new
REM sleep behavior disorder severity scale (RBDSS) for clinical
routine. J Clin Sleep Med 7:75–80
63. Tandberg E, Larsen JP, Karlsen K (1998) A community-based
study of sleep disorders in patients with Parkinson’s disease. Mov
Disord 13:895–899
64. Tandberg E, Larsen JP, Karlsen K (1999) Excessive daytime
sleepiness and sleep benefit in Parkinson’s disease: a community-
based study. Mov Disord 14:922–927
J Neurol (2012) 259:2031–2040 2039
123
65. Thannickal TC, Lai YY, Siegel JM (2007) Hypocretin (orexin)
cell loss in Parkinson’s disease. Brain 130:1586–1595
66. Trenkwalder C, Kohnen R, Hogl B, Metta V, Sixel-Doring F,
Frauscher B, Hulsmann J, Martinez-Martin P, Chaudhuri KR
(2011) Parkinson’s disease sleep scale-validation of the revised
version PDSS-2. Mov Disord 26:644–652
67. Trenkwalder C, Kies B, Rudzinska M, et al (2011) Rotigotine
effects on early morning motor function and sleep in Parkinson’s
disease: a double-blind, randomized, placebo-controlled study
(RECOVER). Mov Disord 26:90–99
68. Trotti LM, Bliwise DL (2010) No increased risk of obstructive
sleep apnea in Parkinson’s disease. Mov Disord 25:2246–2249
69. Valko PO, Waldvogel D, Weller M, Bassetti CL, Held U,
Baumann CR (2010) Fatigue and excessive daytime sleepiness in
idiopathic Parkinson’s disease differently correlate with motor
symptoms, depression and dopaminergic treatment. Eur J Neurol
17:1428–1436
70. Verbaan D, van Rooden SM, van Hilten JJ, Rijsman RM (2010)
Prevalence and clinical profile of restless legs syndrome in
Parkinson’s disease. Mov Disord 25:2142–2147
71. Wetter TC, Collado-Seidel V, Pollmacher T, Yassouridis A,
Trenkwalder C (2000) Sleep and periodic leg movement patterns
in drug-free patients with Parkinson’s disease and multiple
system atrophy. Sleep 23:361–367
72. Yamaguchi M, Arai K, Asahina M, Hattori T (2003) Laryngeal
stridor in multiple system atrophy. Eur Neurol 49:154–159
73. Yasui K, Inoue Y, Kanbayashi T, Nomura T, Kusumi M, Naka-
shima K (2006) CSF orexin levels of Parkinson’s disease,
dementia with Lewy bodies, progressive supranuclear palsy and
corticobasal degeneration. J Neurol Sci 250:120–123
2040 J Neurol (2012) 259:2031–2040
123
